

Erratum to: Differences in metabolic and mitogenic signalling of insulin glargine and AspB10 human insulin in rats

N. Tennagels · S. Welte · M. Hofmann · P. Brenk · R. Schmidt · U. Werner

Published online: 24 October 2013
© Springer-Verlag Berlin Heidelberg 2013

Erratum to: Diabetologia
DOI 10.1007/s00125-013-2923-z

This article refers to AspB10 human insulin. Unfortunately, in the title, abbreviations list and two instances on the first page of the article, the misleading term ‘insulin aspart B10’ was used. The correct title is shown above, and the other sentences are corrected below:

Abstract (second sentence):

AspB10 human insulin (AspB10), the only insulin analogue with proven carcinogenic activity, has a greater affinity for IGF1R and IR, and a prolonged IR occupancy time.

Abbreviations

AspB10 AspB10 human insulin

Introduction (second paragraph, first sentence)

The insulin analogue AspB10 human insulin (AspB10) was withdrawn from clinical development due to a higher incidence of breast cancer in rats [3].

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-013-2923-z>.

N. Tennagels (✉) · S. Welte · M. Hofmann · P. Brenk ·
R. Schmidt · U. Werner
Sanofi-Aventis Deutschland GmbH, Building H821, Room 231,
Industriepark Hoechst,
65926 Frankfurt am Main, Germany
e-mail: norbert.tennagels@sanofi.com